Closantel缓释剂对实验感染肝片吸虫山羊机体自由基影响的研究

选用5只实验感染肝片吸虫山羊研究Closantel缓释剂对机体抗氧化功能的影响，实验用山羊每只一次性口服肝片吸虫囊蚴150个，感染后第15周随机将山羊分成对照组（n=2）和驱虫组（n=3），驱虫组每羊口服两颗Closantel缓释剂，每周定时采集颈静脉血液，检测血清抗氧化酶的变化，观察服用Closantel缓释剂对其的影响。结果表明投药后山羊血清中GSH－Px、CAT均有不同程度的升高，SOD变化不显著，而脂质过氧化产物MDA含量则下降，提示Closantel的缓释剂型对实验感染肝片吸虫山羊机体的抗氧化产生了影响，对机体有一定保护作用。     

硝氯粉和肝蛭净驱除绵羊肝片吸虫效果的对比试验

分别应用硝氯粉、肝蛭净两种药物,采取口服投药方式,以不同剂量做绵羊肝片吸虫驱虫效果的对比试验。结果表明:硝氯粉按5mg/kg体重驱虫,肝片吸虫虫卵减少率96.85%;肝蛭净按12mg/kg体重驱虫,虫卵减少率96.74%。虽二者的驱虫效果差异不大,但在实际操作中,硝氯粉剂量稍大会出现中毒反应;剂量过小则效果不佳,硝氯粉剂量较难控制。建议养畜户在绵羊肝片吸虫驱虫时最好用肝蛭净。     

硝氯粉和肝蛭净驱除绵羊肝片吸虫效果的对比试验

应用硝氯粉和肝蛭净两种药物,采取口服投药方式,分不同剂量,在绵羊肝片吸虫驱虫方面做了对比试验。结果表明:硝氯粉按5mg/kg体重驱虫,肝片吸虫虫卵减少率96.85%;肝蛭净按12mg/kg体重驱虫,虫卵减少率96.74%;二者的驱虫效果差异不大,但在实际操作中,硝氯粉剂量稍大会出现中毒反应,剂量过小则效果不佳,硝氯粉剂量较难控制。建议养畜户在绵羊肝片吸虫驱虫时最好用肝蛭净。     

本地饲养与引进牛羊感染肝片形吸虫后的驱虫效果比较

长期在肝片形吸虫疫区饲养的牛羊群中，用硫双二氯酚100mg／kg(羊)、60mg／kg(牛)口服 左旋咪唑10mg／kg口服驱虫两次后，蠕虫剖检法查牛羊共10头，在肝脏胆管内查出肝片形吸虫146条；第3次驱虫后，剖检羊5头，找到虫体42条，驱虫效果不理想；从外引进的12头牛羊感染肝片形吸虫后药物驱虫敏感，效果明显，经过3次驱虫后，肝片形吸虫病基本转阴。     

两种驱虫药物驱除羊肝片吸虫的效力试验

应用三氯苯咪唑片剂和氯氰碘柳胺钠注射液,选择6~8月龄自然感染肝片吸虫的绵羊80只进行驱虫试验。结果:(1)三氯苯咪唑片剂5、10、15 mg/kg体重剂量对肝片吸虫的虫卵转阴率、减少率和成虫的驱虫率均达100.0%,对肝片吸虫幼虫的驱虫率分别为93.9%、100.0%和100.0%;(2)氯氰碘柳胺钠注射液5、10、15 mg/kg体重剂量对肝片吸虫的虫卵转阴率分别为60.0%、80.0%和100.0%,减少率分别为89.2%、98.2%和100.0%,对成虫驱虫率均分别为97.9%、100.0%和100.0%,幼虫驱虫率分别为90.7%、94.3%和100.0%;(3)三氯苯咪唑片剂10 mg/kg体重剂量与同剂量对照药物三氯苯咪唑混悬剂的驱虫效果无差异;(4)三氯苯咪唑片剂和氯氰碘柳胺钠注射液3个剂量组试验羊未见异常反应。试验证明,三氯苯咪唑片剂5、10、15 mg/kg体重和氯氰碘柳胺钠注射液10、15 mg/kg体重剂量驱除绵羊肝片吸虫安全高效。驱除绵羊肝片吸虫两种药物的使用剂量,三氯苯咪唑片剂不低于5 mg/kg,氯氰碘柳胺钠注射液不低于10 mg/kg体重。     

波尔山羊寄生虫病的药物驱虫效果试验

为了探索不同药物对波尔山羊体内外寄生虫的驱虫效果,采用杀螨脒、癣净灵、灭虫丁等13种药物进行比较试验.结果表明:600×10- 6桔子皮液离体杀螨时间仅158 min,癣净灵活体动物杀螨时间最短为22 h;建议外用灭虫药物应首选癣净灵;广谱药物阿力佳杀螨时间为24 h,残效期为28 d;按驱虫净15 mg/kg体重+虫净灵10 mg/kg体重剂量,患羊进行口服驱虫,一般2次后,发现首次感染肝片吸虫后的羊只对驱虫药物敏感,效果明显,经3次驱虫后,病羊基本转阴;消化道线虫驱虫试验表明:按5 mg/kg 体重剂量口服Rintal片时,消化道线虫的虫卵减少率,虫卵转阴率,虫卵孵化第三期幼虫减少率和第三期幼虫转阴率较高,且安全,无任何毒副作用.     

三氯苯咪唑混悬剂对牦牛肝片吸虫的驱虫试验

应用三氯苯咪唑混悬剂,选择自然感染肝片吸虫的牦牛60头进行了驱虫试验。结果表明:①三氯苯咪唑混悬剂5mg/kg体重剂量对肝片吸虫的虫卵转阴率、减少率分别为83.3%、90.0%,对成虫的驱净率和驱虫率分别为91.7%、93.8%,对童虫的驱净率和驱虫率分别为83.3%、90.1%;10、15mg/kg剂量对肝片吸虫虫卵转阴率、减少率及成虫、童虫的驱净率和驱虫率均达100%;②三氯苯咪唑混悬剂10mg/kg剂量与同剂量三氯苯咪唑片剂的驱虫效果无明显差异;③三氯苯咪唑混悬剂3个剂量组试验牛未见异常反应。试验证明三氯苯咪唑混悬剂10、15mg/kg剂量驱除牦牛肝片吸虫高效安全,临床使用以10mg/kg剂量为宜。     

3种药物对防治青海绵羊肝片吸虫病的效果观察

选用长效内外驱虫净、多捕达、武四肝蛭清、伊立佳4种药物,按照说明剂量经口服给药对互助县南门峡镇某户1²岁绵羊进行了肝片吸虫病驱虫试验。结果表明:给药7 d后,对照组虫卵减少率为29.75%,武四肝蛭清组虫卵减少率最高为85.22%;15 d后,武四肝蛭清组的虫卵减少率可达100.00%。试验表明:不宜长期连续使用同一种药物进行肝片吸虫病的防治,武四肝蛭清对驱除绵羊肝片吸虫高效安全,适宜当地推广应用。     

一氧化氮在山羊感染肝片吸虫过程中的作用

山羊人工感染肝片吸虫后,用硝酸还原酶法检测血清一氧化氮(NO)含量,感染组山羊(n=5)在羊感染后第1周明显低于对照组山羊(n=4),第2～6周或高或低呈波动趋势,自第6周后明显高于对照组,其中第7～8周达高峰(93.73±17.233μmol/L),第7周P＜0.01,第8、10周P＜0.05;用间接ELISA最早在感染后第2周就可检出IgG抗体,并从第4周起保持高水平,第8～9周达最高峰.血清中NO含量与IgG水平的相关系数r=0.511(P＜0.05,差异显著),而对照组的NO与IgG的相关系数r=0.25(差异不显著);感染山羊在整个试验期间嗜酸性粒细胞(EOS)明显升高,差异明显,其中第8周达峰值(P＜0.01).本试验结果表明NO、IgG和EOS在山羊感染肝片吸虫过程中的变化趋势基本一致,呈正相关,且与虫体在宿主体内的移行、发育密切关联,显示NO、IgG和EOS共同参与宿主抗肝片吸虫感染的作用.     

实验感染肝片吸虫山羊的病理生理学——Ⅲ.细胞因子水平的变化

试验选择6只健康白山羊（经粪便学检查和Dot-ELISA检测，确认无肝片吸虫感染）随机分成Ⅰ、Ⅱ、Ⅲ组，其中Ⅰ、Ⅱ组山羊每只分别1次口服接种200、500个肝片吸虫囊蚴，Ⅲ组作为不感染对照组，每周颈静脉采血1次，连续11周，检测肝片吸虫感染后山羊血清中IL-2、TNF-α水平的变化和外周血淋巴细胞分泌IL-2的能力。结果表明，山羊试验感染肝片吸虫后，Ⅰ组山羊血清IL-2水平在感染后有所下降，而Ⅱ组山羊血清IL-2水平在感染后有所升高；感染不同剂量肝片吸虫的山羊血清TNF-α水平和淋巴细胞IL-2分泌水平均有不同程度的升高，在感染后第1周淋巴细胞就有反应，并且对非特异性刺激原和特异性刺激原的应答都有显著升高。这一结果提示，TNF-α可能参与肝片吸虫对肝的损伤过程，肝片吸虫感染剂量对宿主的IL-2含量影响较大，同时IL-2在宿主防御免疫中有重要作用。     

Comparative efficacy of closantel and triclabendazole against Fasciola hepatica in experimentally infected sheep

The effect of closantel (10 mg/kg orally) and triclabendazole (10 mg/kg orally) on the reappearance of a patent infection of Fasciola hepatica was studied in experimentally infected sheep. The treatments resulted in the interruption of faecal egg output for 11 weeks with triclabendazole and 13 weeks with closantel. Necropsy of untreated control animals revealed a mean burden of 360 flukes with a mean (+/- se) surface area of 171 +/- 64.3 mm2, whereas the fluke burdens in the closantel and triclabendazole-treated animals 14 weeks after treatment were 61 (83 per cent reduction) and 21 (94 per cent reduction), respectively. The surface areas of the flukes in the triclabendazole-group were comparable with the untreated controls (141 +/- 51.8 mm2), but the flukes in the closantel group were markedly smaller (43.1 +/- 26.9 mm2). It is concluded that closantel has, in epidemiological terms, a potency comparable with that of triclabendazole, despite its slightly lower efficacy against the very immature stages.     

Efficacy of clorsulon for the treatment of experimentally induced infections of Fasciola hepatica in goats

A dose titration study was undertaken to determine the efficacy of clorsulon against the adult stage of Fasciola hepatica in goats. Thirty-nine goats were experimentally infected with metacercariae of F hepatica. At 14 weeks after infection, each goat was assigned randomly to 1 of 5 groups. Goats in groups 1 to 4 received a single oral administration of clorsulon at dosages of 3.5, 7, 11, and 15 mg/kg of body weight, respectively. The fifth group of goats (control group) was infected with F hepatica, but were not treated with clorsulon. Postmortem examination of goats at 3 weeks after treatment revealed mean reductions in numbers of flukes of 83, 98, 99, and 100% for groups 1 to 4, respectively. Mean percentage of reduction in eggs following treatment of groups was 82, 98, 100, and 100%, respectively. The clinical effects of clorsulon in 24 goats that were not infected with F hepatica were studied. Goats in groups 1 to 3 received a single oral administration of clorsulon at dosages of 7, 21, and 35 mg/kg, respectively, every other day for a total of 3 doses/goat. Group-4 goats (control group) received a vehicle placebo. Goats in group 3 were subject to postmortem examination at 14 days after dosing. Abnormal signs or lesions that could be attributed to clorsulon were not found in any goat.     

Resistance of Fasciola hepatica against triclabendazole in cattle in Patagonia (Argentina)

In the winter of 2008, cattle on a farm in the province of Neuquen, Argentina died from subacute and chronic liver fluke disease despite four previous treatments with Triclabendazole (TCBZ). In the spring of 2009, a preliminary efficacy test revealed good performance using nitroxynil, whereas TCBZ efficacy was only 18% by egg counts of Fasciola eggs in the faeces. Resistance to Fasciola hepatica to TCBZ has never been reported in South America, so in January of 2010 a controlled trial was conducted to confirm and to define the degree of resistance in this herd. In a clinical trial, the fluke egg output was monitored on Days 14 and 21 and serum enzymes gamma-glutamyl transpeptidase (GGT) and glutamic-oxaloacetic transaminase (GOT) on Days 0 and 21 in 36 calves treated with TCBZ or with closantel. The results showed a reduction of 100% in fluke egg output at Days 14 and 21 for closantel. The mean epg in the TCBZ-treated groups did not decrease. Because of the fact that in this study TCBZ treatment in cattle had no effect, even at double the recommended dose, it is highly indicative that resistance of F. hepatica against TCBZ is present on this farm. The GGT and GOT levels decreased in the closantel-treated group as a result of the treatment at 21 days after dosing. To evaluate the importance of TCBZ resistance in F. hepatica in Argentina, a study on more farms from endemic areas is needed.     

肝片吸虫感染对山羊机体自由基代谢影响的研究

实验选择9只健康、6－10月龄雄性白山羊，经粪便学检查和Dot-ELISA检测，确认无肝片吸虫感染，随机分成感染组（n=5)和对照组（n=4)，试验组每只1次口服接种150个肝片吸虫囊蚴，每周定时从颈静脉采集感染前（0周）和感染后15周血液1次分离血清。测定血清谷胱甘肽过氧化物酶（GSH－Px)活性、超氧化物歧化酶（SOD）活性、过氧化物酶（CAT）活性、丙二醛（MDA）和一氧化氮含量的变化，结果表明肝片吸虫感染后血清中GSH－Px活性除第8周试验组显著高于对照组，其他各周无显著差异；在整个实验期间，试验组山羊血清中SOD活性在1－5周呈波动状，以后两组基本处于同一水平；试验组山羊血清CAT活性在感染后第3周显著低于对照组，第6－15周时，试验组始终高于对照组，但各周差异均不显著；试验组山羊血清中MDA含量在整个实验期间始终呈波动状，而在第8、9周试验组显著高于对照组，中周与对照组相比无显著差异；感染后试验组血清中NO开始下降，并且显著低于对照组，至第3－6周时试验组显著高于或低于对照组，第6－15周，试验组一直高于对照组，并在第7、10周时显著地高于对照组。提示山羊感染肝片吸虫后，机体发生多种功能的改变，机体的自由基产生与清除处于相互对抗之中，机体的自由基代谢参与了肝片吸虫病的发展过程。     

Efficacy and safety of clorsulon used concurrently with ivermectin for control of Fasciola hepatica in Florida beef cattle

The safety and anthelmintic efficacy of clorsulon (7 mg/kg of body weight, orally) given concurrently with ivermectin (0.2 mg/kg, subcutaneously) for control of Fasciola hepatica were evaluated in 75 crossbred beef cattle. Twenty-three control animals were given only ivermectin. Fluke egg counts were significantly lower (P less than 0.0001) in clorsulon-treated animals by day 14 after treatment than before treatment (base line) and were significantly lower (P less than 0.005) after treatment in clorsulon-treated animals than in controls. There was no significant change in fluke egg counts of controls after treatment. The efficacy of clorsulon in reducing F hepatica egg counts was 99%. Clorsulon showed poor efficacy against paramphistomes. Adverse reactions were not observed.     

Fasciola in horses in the Republic of South Africa: a single natural case of Fasciola hepatica and the failure to infest ten horses either with F. hepatica or Fasciola gigantica

The faeces of 11 horses were examined for Fasciola spp. eggs. One of them was positive for Fasciola hepatica, a finding which was confirmed post-mortem. The 10 negative horses were subsequently infested with either F. hepatica or Fasciola gigantica, each animal receiving orally from 500-9,500 metacercariae. No clinical signs were observed and no fluke eggs were detected in the faeces, and neither immature nor adult Fasciola worms were recovered from the horses slaughtered 16-26 weeks post-infestation with F. hepatica and 28-34 weeks post-infestation with F. gigantica, respectively. The results indicate that horses have a high level of resistance to both South African Fasciola spp. Factors which can probably explain the conflicting reports for the prevalences of fascioliasis in horses throughout the world and the varying results obtained in experimental infestations are briefly considered.     

Field trial on comparative efficacy of four fasciolicides against natural liver fluke infection in cattle

A controlled trial was conducted to evaluate the current efficacy of albendazole (ABZ), rafoxanide (RFX), triclabendazole (TRC) or clorsulon (CLS) against Fasciola hepatica in naturally infected cattle. This trial was conducted in Turkey during the spring, the time of year when liver fluke infection is endemic. Fifty crossbred cattle were selected for inclusion in the trial based on finding eggs of F. hepatica in the feces. The cattle were weighed and randomly allotted into five groups of 10 cattle and treatments were as follows: Group 1 served as non-treated control (CONT), Group 2 was treated orally with ABZ at 12 mg/kg, Group 3 was treated orally with RFX at 10 mg/kg, Group 4 received TRC orally at 12 mg/kg and Group 5 received CLS administered subcutaneously (s.c.) at 2 mg/kg. On day 0 (inclusion day), individual fecal samples were collected on days 0 (inclusion day), 7, 14, 28 and 56, after treatment. The drug efficacy was assessed as a percentage of the egg or fluke reduction and body weight gain relative to the untreated control. The results in the study showed a mean reduction of egg counts by 66.7%, 68.2%, 78% and 84.2% in Groups 2-5, respectively. In conclusion, our results indicate that CLS is a highly effective compound for the treatment of F. hepatica in cattle under these field conditions.     

Diagnosis of Fasciola hepatica infection in beef calves by plasma enzyme analysis

Plasma analysis for albumin, total bilirubin, and total protein values and aspartate aminotransferase (AST), arginase, and gamma-glutamyl transpeptidase (GGT) activities was used for the early and quantitative diagnosis of experimental Fasciola hepatica infections in beef calves. Calves were infected on 3 occasions with 1,000 (n = 5), 100 (n = 5), or 10 (n = 4) metacercariae for a total infective dose of 3,000, 300, or 30, respectively. Albendazole (15 mg/kg of body weight) was administered to 7 infected calves on postinfection (initial) week (PIW) 13. All calves were euthanatized and necropsied on PIW 16 for the determination of fluke infections. Plasma constituents were determined weekly. Significant (P less than 0.05) increases in AST activity occurred as early as PIW 4 and GGT activity at PIW 9, as compared with that in noninfected controls. Fluke burden-related differences were observed in GGT activity from PIW 9 onward. Increases in AST activity reflected parenchymal liver damage, whereas increases in GGT reflected hepatobiliary damage; therefore, differentiation could be made between the migratory and ductal phases of the infection. There was no correlation between arginase activity and fluke infection. As compared with fecal examination results, plasma enzyme analysis gave an earlier and semiquantitative indication of F hepatica infection in experimentally infected calves. Although increases in these plasma constituents were not definitely diagnostic of fascioliasis, useful information on the size of the fluke burden and progress of the disease process could be obtained by these methods. Plasma enzyme analyses of AST and GGT were not indicative of chemotherapeutic success or failure when calves with mature F hepatica (14 weeks old) infections were treated.     

Flukicidal action of closantel against immature and mature Fasciola hepatica in experimentally infected rats and sheep

The relative importance of peak level- and residual level-related flukicidal activity of closantel against immature and mature Fasciola hepatica was evaluated in a comparative efficacy trial using two animal species with a different plasma elimination pattern, that is, the rat and the sheep with an elimination half-life of less than one week and of two to three weeks, respectively. The rats were dosed orally with closantel at 20 mg kg-1 at two, four, six, eight and 10 weeks; the sheep at 10 mg kg-1 at eight, 10 and 12 weeks after artificial infection. Necropsy was performed either one week after treatment or 12 weeks after infection. Efficacy rates and the length of the recovered flukes were evaluated. It was demonstrated that the flukicidal effect of closantel is directly related to its peak plasma levels and less to its residual plasma concentrations. In the rat, a high efficacy (P less than 0.001) could be demonstrated against immature stages of four weeks or older. The two-week immature stages were less markedly affected. No significant differences in efficacy and size of the flukes were noted between the animals autopsied one week after treatment and those autopsied 12 weeks after infection. In the sheep, the efficacy against six-week and eight-week-old immature stages varied between 70.3 and 76.8 per cent and between 92.8 and 96.5 per cent, respectively. As in the rats, no marked differences in efficacy were noted between the animals autopsied one week after treatment and those autopsied 12 weeks after infection.(ABSTRACT TRUNCATED AT 250 WORDS)     

Fasciola hepatica infection in farmed emus (Dromaius novaehollandiae)

Objective To describe two cases of infection with Fasciola hepatica i n young farmed emus, subacute and chronic fasci-olosis and a response to treatment of the flock with albenda-zole.
Procedure Gross lesions were found at necropsy and hepatic lesions in microscopic examination. The parasite recovered from one emu was identified by its morphological characteristics and an egg count reduction test was carried out after treatment of the flock with albendazole.
Results Hepatic lesions resembling subacute and chronic fasciolosis of ruminants were identified. An adult fluke was recovered from the liver of one of the birds and was identified as F hepatica . The eggs of the fluke were irregular in shape and size. No fluke eggs were identifiable in faeces of live emus 10 days after treatment of the flock with albendazole at a dose of 10 mg/kg.
Conclusions This is the first reported case of infection with F hepatica i n farmed emus and the first report of the occurrence of Fasciola infection is the class Aves. The irregular shape and size of the eggs may be attributable to infection of an aberrant host. Treatment with albendazole eliminated eggs from the faeces of the flock.